迷幻药通过直接与BDNF受体TrkB结合来促进可塑性
Rafael Moliner1,2, Mykhailo Girych3, Cecilia A Brunello1
1Neuroscience Center, HiLIFE, University of Helsinki, Helsinki, Finland.
Nature neuroscience
|June 6, 2023
概括
迷幻药和抗抑郁药准TrkB受体,影响神经可塑性和抗抑郁药的作用. 这项研究揭示了迷幻药与TrkB具有高度亲和力,这表明了独立于幻觉性质的新治疗途径.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 精神病学是一个精神病学.
背景情况:
- 抗抑郁药,包括素和胺,通过结合TrkB受体起作用.
- 迷幻药显示出快速而持久的抗抑郁作用,诱导神经可塑性.
- 精确的分子标和背后的迷幻抗抑郁药作用的机制仍在调查中.
研究的目的:
- 为了研究迷幻药与TrkB受体的直接结合.
- 阐明TrkB激活在迷幻药的抗抑郁药类效应中的作用.
- 为了区分迷幻抗抑郁药效应的机制与其幻觉性质.
主要方法:
- 在体外结合测试以确定对TrkB受体的亲和力.
- 评估神经变信号传递和可塑性,以应对迷幻药和抗抑郁药.
- 用小鼠进行行为研究,以评估类似抗抑郁药的效果.
- 药理学操作以评估TrkB和血清素2A (5-HT2A) 受体的作用.
主要成果:
- Lysergic acid diethylamide (LSD) 和psilocin直接与TrkB结合,相比其他抗抑郁药的亲和力要高得多.
- 在小鼠中,迷幻诱导的神经可塑性和类似抗抑郁药的行为取决于TrkB激活和BDNF信号传递.
- 由LSD诱导的头行为是由5-HT2A受体激活的介导,独立于TrkB结合.
结论:
- TrkB 作为迷幻药和传统抗抑郁药的共同首要目标.
- 没有5-HT2A活性的高亲和力TrkB调节器可以提供幻觉药的抗抑郁药效益,而没有幻觉副作用.
- 这项研究确定TrkB是抗抑郁药作用的关键调解者,为新的治疗策略开辟了道路.
相关概念视频
Enzyme-linked Receptors
78.9K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
78.9K
CNS Stimulants: Psychedelic Agents
193
Hallucinogens, also known as psychedelic drugs, are a class of substances known for their ability to alter perception, cognition, and emotions. Despite their profound effects on the mind, these drugs are non-addictive, setting them apart from many other abused substances. The mechanism of action of these drugs lies in their impact on the 5-HT2A receptor in the brain. Upon activation, this receptor couples to Gq-type G proteins, triggering a cascade that releases intracellular calcium. This...
193
Neuroplasticity
604
Neuroplasticity reflects the brain's remarkable capacity to adapt and evolve, responding dynamically to learning, experiences, or injury by reorganizing its neural circuitry. This reorganization involves creating new neural connections and refining old ones through a series of biological processes that contribute to the brain's lifelong development and adaptability.
604
Long-term Potentiation
2.8K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
Hebbian LTP
LTP can occur when...
Hebbian LTP
LTP can occur when...
2.8K
Hallucinogens and Psychedelics
215
Hallucinogens are psychoactive substances that profoundly alter perceptual experiences, generating unreal visual and sensory images. Often referred to as psychedelic drugs — a term derived from the Greek words "psyche" (mind) and "delos" (revealing) — these substances include marijuana and lysergic acid diethylamide (LSD), among others. These drugs vary in intensity and effects.
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...
215
Drugs Affecting Neurotransmitter Release or Uptake
1.1K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.1K


